MedTrace Logo

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

NCT06253130 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 156

Last updated 2026-03-23

No results posted yet for this study

Summary

This study investigates the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EIK1003 in participants with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

IMP1734

PARP1 selective inhibitor

Sponsors & Collaborators

  • Impact Therapeutics, Inc.

    collaborator INDUSTRY

  • Eikon Therapeutics

    lead INDUSTRY

Principal Investigators

  • Viola Chen, MD · Eikon Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-11
Primary Completion
2027-06-01
Completion
2027-12-01
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • China
  • Denmark
  • France
  • South Korea
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06253130 on ClinicalTrials.gov